Acute Hepatic Allograft Rejection in Pediatric Recipients: Independent Factors

S. M. Dehghani¹, I. Shahramian²*, M. Afshari³, M. Bahmanyar¹, M. Ataollahi¹, A. Sargazi⁴

¹Division of Gastroenterology, Department of Pediatrics, Shiraz University of Medical Sciences, Shiraz, Iran
²Division of Gastroenterology, Department of Pediatrics, Zabol University of Medical Sciences, Zabol, Iran
³Department of Community Medicine, Zabol University of Medical Sciences, Zabol, Iran
⁴Student Research Committee, Zabol University of Medical Sciences, Zabol, Iran

ABSTRACT

Background: Acute cellular rejection (ACR) has a reversible effect on graft and its survival.

Objective: To evaluate the relation between ACR and clinical factors in recipients of liver transplant allografts.

Methods: 47 consecutive liver recipients were retrospectively studied. Their data were extracted from records and analyzed.

Results: 38 (81%) of the 47 recipients experienced ACR during a 24-month follow-up. The rate of rejection was associated with none of the studied factors—recipient’s blood group, sex, age, familial history of disease, drugs and blood products received, type of donor, and Child score and class.

Conclusion: During a limited follow-up period, we did not find any association between ACR and suspected risk factors.

KEYWORDS: Graft rejection; Immunity, cellular; Liver transplantation; Pediatric

INTRODUCTION

Nowadays, liver transplantation is an accepted treatment for end-stage liver diseases in pediatric patients [1]. The first attempt for liver transplantation was done by Starzel in 1963 on a 3-year-old boy with biliary atresia [2]. Despite of the technological, medical and surgical improvements, liver transplantation is associated with mortality and morbidity. Acute cellular rejection (ACR) is one of the main post-transplantation complications affecting the graft function [3-5].

The incidence of ACR in children following liver transplantation was reported differently from <20% to 50% based on age of recipient (in older children it is more frequent); it can occur at any time after the transplantation [6]. Suspicion for ACR is made by chemical and biochemical evidence and the liver biopsy is mandatory for confirmation of the diagnosis. Histological criteria for ACR are based on Sensor’s triad of portal hepatitis, endotheliitis, and lymphocytic cholangitis [7].

Because of reversibility and the impact of ACR on long-term graft function as well as graft loss, this study was conducted to evaluate the impact of pre-transplantation, concomitant and post-transplantation factors of ACR in recipients of allograft liver.

MATERIALS AND METHODS

Between 2012 and 2015, 318 pediatric patients with congenital hepatic disease received liver transplantation in Nemazi Hospital affiliated to Shiraz University of Medical Sciences. Complete records of 47 consecutive pe-
Table 1: Characteristics of patients with acute liver transplant rejection

| Factors                             | n (%) |
|-------------------------------------|-------|
| Sex                                 |       |
| Male                                | 22 (46) |
| Female                              | 25 (52) |
| Blood group                         |       |
| A                                    | 17 (35) |
| B                                    | 10 (21) |
| O                                    | 19 (40) |
| AB                                   | 1 (2)  |
| Family history                      |       |
| No                                   | 35 (75) |
| Yes                                  | 12 (26) |
| Spironolactone before transplantation|       |
| No                                   | 25 (53) |
| Yes                                  | 22 (47) |
| Furosemide before transplantation   |       |
| No                                   | 40 (85) |
| Yes                                  | 7 (15)  |
| Donor type                          |       |
| Dead                                 | 34 (72) |
| Father                               | 3 (6)  |
| Mother                               | 10 (21) |
| Irradiated packed red cells before transplantation |       |
| No                                   | 34 (72) |
| Yes                                  | 13 (28) |
| Whole blood before transplantation  |       |
| No                                   | 32 (68) |
| Yes                                  | 15 (32) |
| FFP before transplantation          |       |
| <4 units                             | 44 (94) |
| >4 units                             | 3 (6)  |

Statistical Analysis

The crude and adjusted associations between potential risk factors and acute rejection were estimated using univariate and multivariate (controlling for treatment delay, Child class, and administration of spironolactone and whole blood transfusion before transplantation) poisson regression models. All statistical analyses were performed with Stata SE ver 11. A p value <0.05 was considered statistically significant.

RESULTS

A total of 47 patients who underwent liver transplantation was followed for a mean±SD of 1.8±1.9 years. The mean±SD age of participants was 9.6±9.6 years; 25 (53%) patients were female; 33 (72%) received transplant from dead donors, the remaining received transplants from their live parents.

Characteristics of patients with ACR are shown in Tables 1, and 2. Univariate analysis revealed that blood transfusion before transplantation increased the risk of ACR (RR=2.79, p=0.04). However, after adjusting for confounders, in a multivariate analysis, the risk was found to be non-significant (p=0.2) (Table 3).

DISCUSSION

In this study, we observed 47 cases of ACR among 318 liver transplant recipients. We found that ACR was not associated with any of the factors investigated before and after the surgery. Multivariate analysis, showed that only receiving irradiated packed red cells before surgery had a borderline significant association with ACR—receiving irradiated packed red cells caused approximately a four-fold increase in the risk of rejection. Wang, et al, conducted a retrospective study for evalu-
ation of ACR risk factors on 110 consecutive liver recipients and found a significant relation between recipients age and ACR. Their explanation for this association was a higher CD8 lymphocyte count in younger patients [8]. Shindoh, et al, performed a prospective study on records of 413 patients who received graft from living donors. They concluded that autoimmune liver diseases are associated with higher risk for ACR and its relapse [9].

Fan, et al, compared the incidence and severity of ACR between living-donor and cadaveric liver transplant recipients. They found no significant difference between groups; also,

| Factors                                | Crude RR (95% CI) | Adj RR (95% CI) |
|----------------------------------------|-------------------|-----------------|
| Irradiated packed red cells before transplant | 1.28 (0.58–2.82)  | 3.84 (0.89–16.62) |
| Irradiated packed red cells during surgery | 1.00 (1.00–1.00)  | 1.00 (0.99–1.01)  |
| Whole blood before transplant          | 2.79 (1.04–7.52)  | 3.19 (0.48–21.07) |
| FFP before surgery                     | 0.72 (0.22–2.34)  | 1.72 (0.40–7.36)  |
| FFP during surgery                     | 1.03 (0.96–1.10)  | 1.29 (0.77–2.17)  |
| Blood group (compared with A)          |                   |                 |
| B                                      | 0.72 (0.31–1.68)  | 0.36 (0.08–1.59)  |
| O                                      | 0.61 (0.29–1.29)  | 0.38 (0.10–1.36)  |
| AB                                     | 0.59 (0.08–4.52)  | 0.60 (0.06–5.92)  |
| Sex                                    | 1.40 (0.74–2.64)  | 1.33 (0.39–4.53)  |
| Age                                    | 1.01 (0.95–1.06)  | 0.93 (0.70–1.24)  |
| Weight                                 | 0.99 (0.96–1.02)  | 1.00 (0.93–1.08)  |
| Familial history                       | 0.86 (0.35–2.12)  | 1.01 (0.21–4.85)  |
| MELD-PELD                              | 0.98 (0.94–1.03)  | 1.01 (0.90–1.15)  |
| Child score                            | 0.95 (0.81–1.11)  | 0.66 (0.28–1.52)  |
| Child class                            | 0.57 (0.29–1.10)  | 0.78 (0.22–2.73)  |
| Furosemide before surgery              | 0.92 (0.38–2.20)  | 1.97 (0.30–13.01) |
| Spironolactone before surgery          | 0.56 (0.29–1.07)  | 0.85 (0.20–3.54)  |
| Albumin before surgery                 | 0.90 (0.71–1.14)  | 1.24 (0.68–2.27)  |
| Donor type (compared with dead)        |                   |                 |
| Father                                 | 1.11 (0.34–3.68)  | 1.25 (0.13–11.50) |
| Mother                                 | 0.62 (0.28–1.36)  | 0.50 (0.09–2.61)  |
| Cold ischemia                          | 1.00 (0.98–1.01)  | 0.99 (0.96–1.02)  |
| Warm ischemia                          | 1.00 (0.97–1.02)  | 0.99 (0.94–1.04)  |
| Infection                              | 1.02 (0.14–7.46)  | 1.28 (0.17–9.68)  |
| Drug allergy                           | 2.96 (0.40–21.58) | 2.96 (0.40–21.58) |
| Treatment delay                        | 1.03 (0.99–1.07)  | 1.01 (0.83–1.22)  |
HLA mismatch and cold ischemic time had no impact on the incidence and severity of ACR \cite{10}. These findings are in keeping with those observed in our study. Toyoki, et al., evaluated the immunological advantage of living-related liver transplantation compared with cadaveric transplants in 100 pediatric liver recipients. They confirmed a comparable incidence of ACR between groups in the first 24 months of transplantation. However, ACR episodes after one year were significantly lower in living-related transplants in 100 pediatric liver recipients. Similar to our results, in a systemic review and meta-analysis carried out by Hu, et al., ACR and graft survival rates were not related to donor types (alive or cadaveric) \cite{12}. Sandra, et al., in their study on 114 pediatric patients reported a higher incidence of ACR in maternal grafts with sex mismatch \cite{13}, which was in contrast to the results of the current study.

Kinpan and his colleagues retrospectively investigated the information of 778 liver recipients to assess the impact of clinical factors on ACR incidence. They concluded that old age, chronic hepatitis B, living donor, and use of interleukin-2 receptor agonists were associated with lower incidence of ACR \cite{14}. Unfortunately, we could not record the exact date of many events. Therefore, survival analysis was not possible for our data; only the associations were investigated during a limited follow-up period from the each participant entry to March 2016. Moreover, because our data were collected and analyzed retrospectively, some necessary data might be ignored during the study.

In conclusion, our study did not find any risk factors for liver transplant rejection. Further multicenter cohorts with larger sample size and longer follow-up period are required to identify the independent risk factors of transplant rejection after liver transplantation.

**CONFLICTS OF INTEREST:** None declared.

**REFERENCES**

1. Dehghani SM, Efazati N, Shahramian I, et al. Evaluation of cholestasis in Iranian infants less than three months of age. *Gastroenterol Hepatol Bed Bench* 2015;8:42-8.
2. Colombani PM, Dunn SP, Harmon WE, et al. Pediatric transplantation. *Am J Transplant* 2003;3:53-63.
3. Tredger JM, Brown NW, Dhawan A. Immunosuppression in pediatric solid organ transplantation: opportunities, risks, and management. *Pediatr Transplant* 2006;10:879-92.
4. Wiesner RH, Demetris AJ, Belle SH, et al. Acute hepatic allograft rejection: incidence, risk factors, and impact on outcome. *Hepatology* 1998;28:638-45.
5. Maluf DG, Stravitz RT, Cotterell AH, et al. Adult Living Donor Versus Deceased Donor Liver Transplantation: A 6-Year Single Center Experience. *Am J Transplant* 2005;5:149-56.
6. Batts KP. Acute and chronic hepatic allograft rejection: pathology and classification. Liver transplantation and surgery. *Liver Transpl Surg* 1999;5 Suppl 1):S21-9.
7. Rodríguez-Perálvarez M, Rico-Juri JM, Tsochatzis E, et al. Biopsy-proven acute cellular rejection as an efficacy endpoint of randomized trials in liver transplantation: a systematic review and critical appraisal. *Transpl Int* 2016;29:961-73. doi: 10.1111/tri.12737.
8. Wang Y-C, Wu T-J, Wu T-H, et al. The risk factors to predict acute rejection in liver transplantation. *Transplant Proc* 2012;44:526-8. doi: 10.1016/j.transproceed.2012.01.050.
9. Shindoh J, Akamatsu N, Tanaka T, et al. Risk factors for acute liver allograft rejection and their influences on treatment outcomes of rescue therapy in living donor liver transplantation. *Clin Transplant* 2016;30:880-5. doi: 10.1111/citr.12760 2016.
10. Fan S, Zhang Z. [Comparison of acute cellular rejection between living donor liver transplantation and cadaveric liver transplantation]. *Zhonghua Yi Xue Za Zhi* 2001;81:1092-4. [in Chinese]
11. Toyoki Y, Renz JF, Mudge C, et al. Allograft rejection in pediatric liver transplantation: Comparison between cadaveric and living related donors. *Pediatr Transplant* 2002;6:301-7.
12. Hu A, Liang W, Zheng Z, et al. Living donor vs. deceased donor liver transplantation for patients with hepatitis C virus-related diseases. *J Hepatol* 2012;57:1228-43. doi: 10.1016/j.jhep.2012.07.015.
13. Sanada Y, Kawano Y, Miki A, et al. Maternal grafts protect daughter recipients from acute cellular rejection after pediatric living donor liver transplantation for biliary atresia. *Transpl Int* 2014;27:383-90. doi: 10.1111/tri.12273.
14. Au KP, Chan S-C, Chok KS-H, et al. Clinical factors affecting rejection rates in liver transplantation. *Hepatobiliary Pancreat Dis Int* 2015;14:367-73.